Trial Profile

Phase II, Multi-Centre, Open-Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database.
15 Dec 2016 Results assessing efficacy and safety of sorafenib in treatment-naive patients with metastatic renal cell carcinoma published in the BJU International.
03 Jul 2013 New source identified and integrated (German Clinical Trials Register; DRKS00004057).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com